Data from murine models suggest that competition for iron within the bone marrow microenvironment occurs in the initial stages of MM-related anemia, which would make hepcidin- or cytokine-targeted therapy less effective in newly diagnosed patients [33]. The gene discussed is HAMP; the disease is Miyoshi myopathy.